Core Insights - Precision BioSciences announced that new preclinical study data for PBGENE-DMD will be presented at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference, highlighting its potential safety and long-term efficacy [1] Company Overview - Precision BioSciences, Inc. is a clinical-stage gene editing company utilizing its proprietary ARCUS® platform to develop in vivo gene editing therapies for diseases with high unmet needs [1] - The company has received Investigational New Drug clearance from the U.S. FDA for PBGENE-DMD, allowing the initiation of clinical trial site activation [1] Product Details - PBGENE-DMD is a first-in-class gene editing therapy designed to provide durable functional muscle improvement for Duchenne Muscular Dystrophy (DMD) patients with mutations between exons 45 and 55, affecting up to 60% of boys with DMD [1] - The therapy employs a gene excision approach, differentiating it from existing treatments like microdystrophin and exon skipping [1] - Preclinical studies demonstrated significant and durable functional improvements in a humanized DMD mouse model, restoring production of a near full-length functional dystrophin protein across multiple muscle types [1] Clinical Development - The upcoming presentation at the MDA conference will focus on the abstract titled "PBGENE-DMD gene editing treatment leads to safe and long-term functional improvement in humanized DMD-disease mouse model" [1] - The presentation is scheduled for March 9, 2026, and will be a poster presentation [1]

Core Viewpoint - Precision BioSciences, Inc. has received a Study May Proceed notification from the U.S. FDA, enabling the company to start clinical trial activities for its FUNCTION-DMD Phase 1/2 trial [1] Group 1 - The company specializes in gene editing using its proprietary ARCUS® platform to develop therapies for diseases with high unmet needs [1] - The FDA's notification allows Precision BioSciences to initiate Institutional Review Board (IRB) activities and activate clinical trial sites [1]

Financial Outlook - As of December 31, 2025, Precision BioSciences expects to report approximately $137 million in cash, cash equivalents, and restricted cash[8] - The company anticipates that its cash runway will extend through 2028, supported by existing cash, potential near-term licensee considerations, and fiscal discipline[9] Clinical Trials - Additional biopsy data from the ELIMINATE-B trial for PBGENE-HBV is expected in the first half of 2026[12] - The FUNCTION-DMD Phase 1/2 clinical trial in Duchenne muscular dystrophy patients is expected to dose the first patient in late Q1 or early Q2 2026, with initial data anticipated by year-end 2026[13] Strategic Priorities - The company has set strategic priorities for 2026, as announced in a press release on January 12, 2026[10]

Core Viewpoint - Precision BioSciences, Inc. is advancing its gene editing therapies through its proprietary ARCUS® platform, focusing on unmet medical needs and outlining strategic priorities for 2026, with significant progress in its lead programs and a strong financial position to support upcoming milestones [1][2]. Clinical Programs - The PBGENE-HBV program is in a Phase 1/2a ELIMINATE-B trial aimed at curing chronic Hepatitis B by eliminating cccDNA, with positive dose-dependent effects and antiviral activity reported [3][4]. - Safety data from the PBGENE-HBV trial indicated no dose-limiting toxicities at doses up to 0.8 mg/kg, with manageable adverse events observed [4][5]. - Additional dosing cohorts are being explored to optimize the therapeutic index, with 12 participants having completed at least one dose administration [5][6]. - The PBGENE-DMD program is set to begin its Phase 1/2 FUNCTION-DMD trial in late Q1 or early Q2 2026, targeting DMD patients with specific mutations, with initial data expected by the end of 2026 [8][10]. Partnered Programs - ECUR-506, developed by iECURE, is being evaluated for neonatal onset OTC deficiency and has received FDA RMAT designation, with data expected in the first half of 2026 [11]. - The azer-cel CAR T treatment is being developed by Imugene for diffuse large B-cell lymphoma, with Precision receiving an $8 million milestone payment due to progress [12]. - Additional milestone payments are anticipated from TG Therapeutics for azer-cel's ongoing Phase 1 trial in progressive multiple sclerosis [13]. Financial Position - Precision BioSciences expects to report approximately $137 million in cash and equivalents as of December 31, 2025, with a cash runway projected through 2028 to support ongoing clinical programs [14].

Core Viewpoint - The article discusses the investment strategy focused on clinical-stage biotech stocks, emphasizing the importance of scientific fundamentals in evaluating these investments [1]. Group 1: Investment Strategy - The investment style is long-only, targeting both long-term ideas and event-driven trading opportunities within the biotech sector [1]. - The author’s academic and medical background provides a unique perspective for assessing the scientific aspects of biotech stocks [1]. Group 2: Analyst's Position - The analyst holds a beneficial long position in the shares of DTIL, indicating confidence in the stock's potential [2]. - The article reflects the author's personal opinions and is not influenced by external compensation [2].

Core Viewpoint - The article discusses the investment strategy focused on clinical-stage biotech stocks, emphasizing the importance of scientific fundamentals in evaluating these investments [1]. Group 1: Investment Strategy - The investment style is long-only, targeting both long-term ideas and event-driven trading opportunities within the biotech sector [1]. - The author’s academic and medical background aids in assessing the scientific fundamentals of biotech stocks, which is crucial for making informed investment decisions [1]. Group 2: Analyst's Position - The analyst holds a beneficial long position in the shares of DTIL, indicating confidence in the stock's potential [2]. - The article reflects the author's personal opinions and is not influenced by compensation from any company mentioned [2].

Summary of Precision BioSciences Conference Call Company Overview - **Company**: Precision BioSciences (NasdaqCM:DTIL) - **Industry**: In-vivo gene editing - **Location**: Durham, North Carolina - **Focus**: Developing gene editing therapies for chronic hepatitis B and Duchenne muscular dystrophy (DMD) [2][3][4] Key Programs PBGene-HBV (Hepatitis B) - **Target Population**: 300 million people globally with chronic hepatitis B [2] - **Current Status**: Program initiated in the clinic late 2024, with ongoing data generation throughout 2025 and into 2026 [3][4] - **Mechanism**: Aims to eliminate cccDNA, the root cause of hepatitis B, rather than just reducing S antigen levels [9][10][12] - **Clinical Trial**: Phase 1 trial named "Eliminate B" with three cohorts, focusing on safety and efficacy [13][14] - **Safety Profile**: Well-tolerated across all doses, with manageable side effects [15][20] - **Data Trends**: Early cohorts show promising reductions in S antigen levels, with cohort three demonstrating sustained reductions [16][18] - **Future Plans**: Completion of cohort three dosing, potential to stop nucleoside analogs, and test for a cure [20][21] PBGene-DMD (Duchenne Muscular Dystrophy) - **Target Population**: Affects boys with a genetic disease leading to muscle loss and early mortality [21][22] - **Current Status**: IND filing expected by the end of 2025, with clinical trials anticipated to start in early 2026 [25][26] - **Mechanism**: Gene editing approach targeting mutations in exons 45 to 55, potentially benefiting up to 60% of DMD patients [22][24] - **Clinical Trial Design**: Phase 1, 2, 3 study design with a focus on safety and efficacy [25][26] Financials - **Recent Financing**: Raised $75 million from existing and new investors, providing a cash runway through 2028 [4] - **Investment Strategy**: Focused on two key programs to maximize capital efficiency and create value inflection points [35] Market Context - **Unmet Needs**: Both hepatitis B and DMD represent significant unmet medical needs, with current treatments lacking effectiveness [21][22][27] - **Competitive Landscape**: Current standard of care for hepatitis B involves nucleoside analogs, which do not address cccDNA, resulting in low functional cure rates (1%-3%) [29][30][31] Strategic Partnerships - **PBGene-HBV**: Potential for strategic partnerships for commercialization, especially for larger phase three trials [32] - **PBGene-DMD**: Opportunities for partnerships exist, but the company is capable of advancing this program independently [33] Future Outlook - **Data Readouts**: Anticipated data readouts for both programs in 2026, with potential for a Biologics License Application (BLA) for DMD by the end of 2028 [26][27] - **Investor Engagement**: Emphasis on demonstrating the effectiveness of gene editing to attract further investment and partnerships [35]

Core Insights - Precision BioSciences (DTIL) has been highlighted for its promising gene-editing programs, which the market has not fully recognized yet [2] Company Overview - The company is involved in developing innovative therapies and pharmaceuticals, with a focus on breakthrough treatments that have potential acquisition catalysts [2] Investment Group - The investment group "Compounding Healthcare" offers features such as model healthcare portfolios, a weekly newsletter, a daily watchlist, and a platform for dialogue and questions among investors [2]

Core Insights - The article discusses Precision BioSciences (DTIL) and its promising gene-editing programs, which have not yet gained significant market attention despite their potential [2]. Group 1: Company Overview - Precision BioSciences is involved in developing innovative gene-editing therapies that could be considered best-in-class within the biotech sector [2]. - The company has a pipeline of programs that are positioned to be breakthrough therapies, indicating strong future growth potential [2]. Group 2: Market Context - Despite positive updates from Precision BioSciences in 2023, the market has largely overlooked the company's advancements, suggesting a disconnect between the company's performance and market perception [2].

Core Points - Precision BioSciences held a business update call for AASLD 2025, featuring key executives including the CEO, CFO, and Chief Scientific Officer [1][2] - The call included a presentation format where speakers referenced specific slides for detailed information [2] Company Overview - The company is focused on advancements in the field of hepatic and infectious diseases, as indicated by the involvement of Dr. Mark Sulkowski, a renowned expert in these areas [1] - The leadership team consists of experienced professionals, highlighting the company's commitment to strong governance and expertise in its operations [1]